Call for Abstract
7th World Congress on Antibiotics, Antimicrobials & Antibiotic Resistance, will be organized around the theme “Antibiotics: Discovery, Resistance, and Alternatives”
Antimicrobials 2019 is comprised of 17 tracks and 49 sessions designed to offer comprehensive sessions that address current issues in Antimicrobials 2019.
Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.
Register now for the conference by choosing an appropriate package suitable to you.
An antibiotic is a sort of medicine which is used for the treatment of bacterial infections. We associate with thousands of bacterial cells every day and colonized by lot of divergent types of bacteria which inside us or on us; almost every part of the body. We need to maintain a healthy ecosystem of bacteria to live healthy, called normal flora (not all bacteria is bad!), while few selectively getting rid of the harmful, “pathogenic” bacteria which may stimulus an infection. Human body’s immune system responds to an infection by trying to fight and destroy the harmful bacteria! To support immune system, humans use antibiotics, which are chemicals (specifically made) that enter and stick to important parts (targets) of the bacterial cell, and restrict its capability to exist and reproduce.
- Track 1-1Introduction
- Track 1-2Mechanism of action of antibiotics
- Track 1-3General principles for the use of antibiotics
- Track 1-4Clinical use of antibiotics
- Track 1-5Epidemiology of infections
- Track 1-6Application of antibiotics
Antibiotic resistance emerge when antibiotics loses the ability to restrict or kill bacterial growth; in other words, the bacteria are "resistant" and progress to multiply in the presence of therapeutic levels of an antibiotic. Antibiotic resistance is a natural aspect. When antibiotic is used, bacteria that can persist the antibiotics have more number of chances to survive than those that are "susceptible." Susceptible bacteria are wiped out or inhibited by an antibiotic, resulting in a selective pressure for the survival of resistant strains of bacteria. Sometimes resistance may occur without any human interaction and sometimes due to overuse of drugs or taking antibiotics unnecessarily which is clearly a human mistake.
- Track 2-1Mechanisms of resistance
- Track 2-2Cause of antibiotic resistance
- Track 2-3Development of antibiotic resistance
- Track 2-4Spread of antibiotic resistance
- Track 2-5Initiatives to facilitate antibiotic development
Antibiotic resistance plays an important and influencing on one’s health as treating an antibiotic resistant infection is difficult. The usage of broad spectrum and narrow spectrum antibiotics by patients should be decided after good consultation with a doctor. The unwanted usage of high doses also causes genetic mutation in bacteria leading to antibiotic resistance. It has been estimated that 700,000 to several million deaths result per year as the resistance is increasing globally as exposure to antibiotic drugs has increased in developing countries.
Virulence is the capability of microorganisms to cause infection. The microbial virulence procedure includes adhesion to host cell, colonization, invasion of host system and releasing immune response inhibitors, toxins. The process includes virulent factors like proteins or other molecules synthesized by the bacterial genes or plasmids, mobile genetic elements etc. As per immunology the factors of infective microorganism triggers the host immune response.
Scientific innovation is a prime rock for global medical service which includes both academic and industrial research. The drug discovery process involves both academic and industrial innovations. The drug development process is as follows: inventing or discovering a compound, preclinical trials on microbes and animals i.e., in-vitro, in-vivo, clinical trials involving patients by clinical research management. Social responsibility and ethics should walk hand in hand with research for a good clinical research management.
- Track 6-1Ozenoxacin
- Track 6-2Solithromycin
- Track 6-3Amikacin Inhale
- Track 6-4Arikayce
- Track 6-5Eravacycline
- Track 6-6MK-3415A
- Track 6-7Cadazolid
- Track 6-8Gepotidacin
- Track 6-9Delafloxacin
- Track 6-10Carbavance
Beta-Lactams. Macrolides. Fluoroquinolones. Tetracyclines. Aminoglycosides are the five major classes of antibiotics. Beta-Lactams are broad spectrum antibiotics that has beta-lactrum ring in structure for example pencillin. Macrolides have a large macrocyclic lactone ring and act against gram positive bacteria. Fluoroquinolones are quonoline compounds containing fluorine atom and acts against gram positive and gram negative bacteria. Tetracycline is in list of WHO of essential list of medicines, tetracyclines are named after their four hydrocarbon rings and are used for patients allergic to Beta-Lactams and Macrolides. Aminoglycosides act against gram negative bactria and streptomycin is one of the best examples of Aminoglycosides.
- Track 8-1Quinolones
- Track 8-2Beta-lactams
- Track 8-3Macrolides
- Track 8-4Others
- Track 9-1Synthetic
- Track 9-2Semisynthetic
There are different classes of antibiotics having different mode of action. Some antibiotics act on cell wall of bacteria, some on DNA synthesis, and some on RNA and protein synthesis. Pencillin, Cephalosporins, Glycopeptides, cycloserines affects synthesis of cell wall. Polymixines, antifungal polyenes, macrolides effects permeability of cell membrane. Rifamycins, Fluorquinolenes affects RNA and DNA sysnthesis. Tetracyclin, Chrloramphenical, Macrolides, Aminoglycosides affects protein sysnthesis.
- Track 10-1Bactericidal
- Track 10-2Bacteriostatic
- Track 11-1Antibiotics for veterinary use
- Track 11-2Antibiotics for human use
Antibiotics are classified into two major class depending on the range of activity against bacterial species i.e,. Broad spectrum antibiotics and Narrow spectrum antibiotics. Broad spectrum antibiotics act against gram positive and gram negative bacteria. For instance tetracycline, phenicols etc. Narrow spectrum antibiotics acts against particular species of bacteria. For instance glycopeptides and polymixins act against gram positive and gram negative bacteria respectively.
- Track 12-1Narrow-spectrum antibiotics
- Track 12-2Broad-spectrum antibiotics
The drug or antibiotic sponsor plays an important role in applying, acquiring information and approval from center for veterinary medicine (CVM). The process is as follows: the sponsor or researcher submits a proposal i.e., “a new animal drug application” (NADA) to CVM. After CVM approves the proposal research, clinical trials, safety trials should be conducted by the sponsor and submits the results to CVM. After a thorough check and audit CVM approves the veterinary drug. The CVM team includes scientists, veterinarians, chemists, biostatistician, microbiologist and toxicologist.
- Track 13-1CNADAs
- Track 13-2NADAs and supplements
- Track 13-3ANADAs and supplements
- Track 13-4ANADAs and supplements
- Track 13-5Animal antibiotics
Global antibiotic market depends on the gap in demand and supply. As per the current analysis the market landscape for antibiotics is boosting due to emergence of infectious diseases like HIV, Pneumonia, Tuberculosis etc,. The sustained usage of antibiotics over few decades all over the world has induced the development of antibiotic resistant microbial species which inturn opened a wide market for research and development of new antibiotics. The spread of different diseases in under developed and developed countries also laid a large platform for market of antibiotics.
- Track 14-1Market overview
- Track 14-2Market size and forecast
The methods undertaken in organizing health care services, subsidy policies, and pharmaceutical marketing strategies should be taken into confidence to justify the different level of use of antibiotics by different countries. According to analysis in 2015 by “European center for disease prevention of OECD health statistics” Turkey stands first in antibiotics usage followed by Greece and France. As per current scenario Asia pacific region is leading in its share for global antibiotic market compared to North America, Europe and Asia.
- Track 15-1Market overview
- Track 15-2Antibiotics market in America
- Track 15-3Antibiotics market in Europe, Middle East, Africa (EMEA)
- Track 15-4Antibiotics market in Asia pacific (APAC)
- Track 16-1Market challenges
- Track 16-2Market drivers
- Track 17-1Increased federal and institutional funding on antibiotic research
- Track 17-2Strategic alliances and mergers and acquisitions (M&A)
- Track 17-3Patient assistance programs (PAPs)